Lantheus announces corporate plans, CAD agent strategy

03/24/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said it is undertaking measures to cut costs, including decreasing internal research and development and obtaining a partner for the final development of its PET radiopharmaceutical for diagnosing coronary artery disease, 18F-flurpiridaz. The partner will help with the remainder of Phase III development and commercialization, Lantheus said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL